NASDAQ:TYRA Tyra Biosciences (TYRA) Stock Price, News & Analysis $20.59 -0.51 (-2.42%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$20.22▼$21.1150-Day Range$16.70▼$22.7652-Week Range$10.38▼$24.25Volume66,986 shsAverage Volume145,178 shsMarket Capitalization$1.08 billionP/E RatioN/ADividend YieldN/APrice Target$24.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Tyra Biosciences alerts: Email Address Tyra Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside20.4% Upside$24.80 Price TargetShort InterestBearish8.35% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$74,040 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.53) to ($1.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.36 out of 5 starsMedical Sector876th out of 910 stocksPharmaceutical Preparations Industry409th out of 426 stocks 2.4 Analyst's Opinion Consensus RatingTyra Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTyra Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Tyra Biosciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.35% of the float of Tyra Biosciences has been sold short.Short Interest Ratio / Days to CoverTyra Biosciences has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.Change versus previous monthShort interest in Tyra Biosciences has recently decreased by 0.45%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTyra Biosciences does not currently pay a dividend.Dividend GrowthTyra Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TYRA. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Tyra Biosciences this week, compared to 2 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tyra Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,040.00 in company stock.Percentage Held by Insiders15.40% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.14% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tyra Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tyra Biosciences are expected to decrease in the coming year, from ($1.53) to ($1.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tyra Biosciences is -12.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tyra Biosciences is -12.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTyra Biosciences has a P/B Ratio of 2.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tyra Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Tyra Biosciences Stock (NASDAQ:TYRA)Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.Read More TYRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TYRA Stock News HeadlinesSeptember 2, 2024 | stockhouse.comAn Inquiry Is Being Made Into Whether Tyra Biosciences Has Defrauded The Public And The Schall Law Firm Wants Shareholders To HelpAugust 27, 2024 | finance.yahoo.comTyra Biosciences, Inc. (TYRA): One of Oppenheimer’s Top Stock Picks For the Next 12 MonthsSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 25, 2024 | finance.yahoo.comTyra Biosciences, Inc. (TYRA) Stock Price, News, Quote & History - Yahoo FinanceAugust 24, 2024 | ca.finance.yahoo.comTYRA Sep 2024 25.000 callAugust 21, 2024 | tmcnet.comTYRA Investors Have Opportunity to Join Tyra Biosciences, Inc. Securities Fraud Investigation with the Schall Law FirmAugust 17, 2024 | finance.yahoo.comTYRA Sep 2024 20.000 call (TYRA240920C00020000)August 16, 2024 | msn.comPiper Sandler Initiates Coverage of Tyra Biosciences (TYRA) with Overweight RecommendationSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 16, 2024 | markets.businessinsider.comBuy Rating for Tyra Biosciences Backed by TYRA-300’s Potential and FGFR ExpertiseAugust 10, 2024 | uk.investing.comTyra Biosciences stock target raised, rating reiterated on study progressAugust 9, 2024 | markets.businessinsider.comBuy Rating Backed by Promising Phase 1 Results and Potential of Tyra Bioscience’s Selective FGFR InhibitorsAugust 9, 2024 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Tyra Bioscience (TYRA)August 8, 2024 | investorplace.comTYRA Stock Earnings: Tyra Biosciences Beats EPS for Q2 2024August 7, 2024 | prnewswire.comTyra Biosciences Reports Second Quarter 2024 Financial Results and HighlightsJuly 22, 2024 | seekingalpha.comLots Of Bullish Signals, But No Revenue Or Earnings From Tyra BiosciencesJuly 21, 2024 | msn.comVirginia General Assembly repeals VMSDEP language, veterans say it’s a ‘slight relief’July 2, 2024 | prnewswire.comTyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)See More Headlines Receive TYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TYRA CUSIPN/A CIK1863127 Webwww.tyra.bio Phone619-728-4760FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$24.80 High Stock Price Target$33.00 Low Stock Price Target$15.00 Potential Upside/Downside+20.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,130,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-27.13% Return on Assets-25.65% Debt Debt-to-Equity RatioN/A Current Ratio36.46 Quick Ratio36.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.12 per share Price / Book2.89Miscellaneous Outstanding Shares52,540,000Free Float44,449,000Market Cap$1.08 billion OptionableOptionable Beta1.01 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Todd Harris Ph.D. (Age 45)Co-Founder, President, CEO, Secretary, Treasurer & Director Comp: $1.07MMr. Alan Fuhrman (Age 67)Chief Financial Officer Comp: $763.09kDr. Hiroomi Tada M.D. (Age 60)Ph.D., Chief Medical Officer Comp: $816.31kMr. Daniel Bensen (Age 48)Co-Founder & COO Comp: $630.8kDr. Robert L. Hudkins Ph.D. (Age 68)Chief Technology Officer Dr. Ronald V. Swanson Ph.D. (Age 60)Chief Scientific Officer Comp: $536.19kMr. Ali D. Fawaz J.D.General CounselMs. Sarah HonigVice President of Corporate Development & StrategyDr. Piyush R. Patel Ph.D. (Age 58)Chief Development Officer Amy ConradInvestor ContactMore ExecutivesKey CompetitorsImmunovantNASDAQ:IMVTCrinetics PharmaceuticalsNASDAQ:CRNXAvidity BiosciencesNASDAQ:RNAADMA BiologicsNASDAQ:ADMABiohavenNYSE:BHVNView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCBought 338,208 shares on 8/16/2024Ownership: 1.908%Ally Bridge Group NY LLCBought 264,660 shares on 8/14/2024Ownership: 0.501%HighVista Strategies LLCBought 16,078 shares on 8/14/2024Ownership: 0.030%Ensign Peak Advisors IncBought 190,557 shares on 8/13/2024Ownership: 0.361%American Century Companies Inc.Bought 145,346 shares on 8/8/2024Ownership: 0.324%View All Insider TransactionsView All Institutional Transactions TYRA Stock Analysis - Frequently Asked Questions How have TYRA shares performed this year? Tyra Biosciences' stock was trading at $13.85 at the start of the year. Since then, TYRA shares have increased by 48.7% and is now trading at $20.59. View the best growth stocks for 2024 here. How were Tyra Biosciences' earnings last quarter? Tyra Biosciences, Inc. (NASDAQ:TYRA) posted its earnings results on Wednesday, August, 7th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.09. When did Tyra Biosciences IPO? Tyra Biosciences (TYRA) raised $100 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share. Who are Tyra Biosciences' major shareholders? Top institutional shareholders of Tyra Biosciences include Perceptive Advisors LLC (1.91%), Ally Bridge Group NY LLC (0.50%), Ensign Peak Advisors Inc (0.36%) and American Century Companies Inc. (0.32%). Insiders that own company stock include Todd Harris, Daniel Bensen, Mva Investors, Llc and Boxer Capital, Llc. View institutional ownership trends. How do I buy shares of Tyra Biosciences? Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TYRA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tyra Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tyra Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TYRA Stock Alerts